Effect of DW2282 on the induction of methemoglobinemia, hypoglycemia or WBC count and hematological changes

Archives of Pharmacal Research

Volumn 22, Issue 6, 1999, Pages 565-570

  Moon, Eun Yi ^a   Hwang, Hyun Sook ^a   Choi, Chung Ha ^a   Jung, Sang Hun ^b   Yoon, Sung June ^a  

^a DongWha Pharm Ind Co   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

ALT; AST; Blood glucose; DW2282; Methemoglobin; WBC

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DW 2282; IMIDAZOLE DERIVATIVE; SULFONE;

ANIMAL; ARTICLE; BLOOD CELL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPOGLYCEMIA; IN VITRO STUDY; MALE; METABOLISM; METHEMOGLOBINEMIA; MOUSE;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BLOOD CELLS; BLOOD GLUCOSE; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOLYSIS; HUMANS; HYPOGLYCEMIA; IMIDAZOLES; MALE; METHEMOGLOBINEMIA; MICE; SULFONES;

EID: 0033249665     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02975327     Document Type: Article

References (28)

1. Beach, E. F. and Turner, J. J., An enzymatic method for glucose determination in body fluids. Clin. Chem., 4, 462-469 (1958).
2. Blum, R. H. and Carter, S. K., Adriamycin : A new anticancer drug with significant clinical activity. Ann. Internal Med., 80, 249-259 (1974).
3. Boder, G. B., Beasley, F. W. and Grindey, G. B., Mechanism of action studies with LY186641. Proc. Amer. Assoc. Cancer Res., 30, abstr. 2203 (1989).
4. Carter, S. K., Adriamycin : A review. J. Natl. Cancer Ins., 55, 1265-1274 (1975).
5. Cornelius, C. E., A review of new approaches to assessing hepatic function in animals. Vet. Res. Commun., 11, 423-441 (1987).
6. Ehlhardt, W. J., Woodland, J. M., Toth, J. E., Ray, J. E. and Martin, D. L., Disposition and metabolism of the sulfonylurea oncolytic agent LY295501 in mouse, rat and monkey. Drug Metabol. Dispos., 25, 701-708 (1997).
7. Evelyn, K. A. and Malloy, H. T., Micro-determination of oxyhemoglobin, methemoglobin and sulfhemoglobin in single sample of blood. J. Biol. Chem., 126, 655-662 (1938).
8. Hainworth, J. D., Hande, K. R., Satterlee, W.G., Kuttesch, J., Johnson, D.H., Grindey, G. B., Jackson, L.E. and Greco, F. A., Phase I clinical study of N-[(4-chlorophenyl)-amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res., 49, 5217-5220 (1989).
9. Houghton, P. J., Bailey, F. C., Germain, G. S., Grindey, G. B., Witt, B. C., Houghton, J. A., N-(5-Indanylsulfonyl)-N-(4-chlorophenyl)urea, a novel agent equally cytotoxic to non-proliferating human colon adenocarcinoma cells. Cancer Res., 50, 318-322 (1990a).
10. Houghton, P. J., Bailey, F. C., Houghton, J. A. , Murti, K. G., Howbert, J. J. and Grindey, G. B., Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N-(4-chlorophenyl)urea in human colon adenocarcinoma cells. Cancer Res., 50, 664-668 (1990b).
11. Houghton, P. J., Bailey, F. C., Germain, G. S., Grindey, G. B., Howbert, J. J. and Houghton, J. A., Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N -(4-chlorophenyl) urea. Biochem. Pharmacol., 39, 1187-1192 (1990c).
12. Houghton, P. J. and Houghton, J. A., Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Invest. New Drugs, 14, 271-280 (1996).
13. Houghton, P. J., Houghton, J. A., Meyers, L., Cheshire, P., Howbert, J. J. and Grindey, G. B., Evaluation of N-(5-indanylsulfonyl)-N-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol., 25, 84-88 (1989).
14. Howbert, J. J., Sulofenur. Drug Future., 16, 517-520 (1991).
15. Howbert, J. J., Grossman, C. S., Crowell, T. A., Rieder, B. J., Harper, R.W., Kramer, K.E., Tao, E.V., Aikins, J., Poore, G. A., Rinzel, S. M., Grindey, G. B., Shaw, W.N. and Todd, G. C., Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities and analysis of quantitative structure-activity relationships. J. Med. Chem., 33, 2393-2407 (1990).
16. Jung, S. H. Song, J. S., Lee, H. S., Choi, S. H. and Lee, C. O., Synthesis and Evaluation of cytotoxicity of novel arylsulfonylimidazolidinones containing sulfonylurea pharmacophore. Arch. Pharm. Res., 19, 570-580 (1996a).
17. Jung, S. H. Song, J. S., Lee, H.S., Choi, S. H. and Lee, C. O. Synthesis and Evaluation of cytotoxicity of novel arylsulfonylimidazolidinones. Bioorg. Med. Chem. Lett. 6, 2553-2558 (1996b).
18. Jung, S. H., Lee, H. S., Song, J. S., Kim, H. M., Han, S. B., Lee, C. W., Lee, M., Choi, D. R., Lee, J. A., Chung, Y. H., Yoon, S. J., Moon, E. Y., Hwang, H. S., Seong, S. K. and Lee, D.K., Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones. Bioorg. Med. Chem. Lett., 8, 1547-1550 (1998).
19. Keston, A. S., Specific colorimetric ezymatic analytical reagents for glucose, Abstract of papers, 129th Meeting, ACS, Dallas, Taxas, April, p31C (1956).
20. Miescher, P. A. and Gerarde, H. W., A one-step method for counting leukocytes and platelets. Am. J. Clin. Pathol., 46, 576-581 (1966).
21. Mohamadi, F., Spees, M. M. and Grindey, G. B., Sulfonylureas: A new Class of Cancer Therapeutic Agents. J. Med. Chem., 35, 3012-3016 (1992).
22. Pfeifer, M. A., Halter, J. B., Beard, J. C. and Porte, D. J., Differential effects of tolbutamide on first and second phase insulin secretion in non-insulin-dependent diabetes mellitus. J. Clin. Endoclinol. Metab., 53, 1256-1262 (1981).
23. Reitman, S. and Frankel, S., A colorimetric method for the determination of serum glutamic axaloacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol., 28, 56-64 (1957).
24. 4-alkyl derivatives of 1-B-D-arabinofuranosylcytosine. J. Cancer Res. Clin. Oncol., 122, 102-108 (1996).
25. Sosinski, J., Thakar, J. H., Germain, G. S., Dias, P., Harwood, F. C., Kuttesch, J. F. and Houghton, P. J., Cross-resistance of antitumor diarylsulfonylureas, and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N-(4-chlorophenyl)urea. Mol. Pharmacol., 45, 962-970 (1994).
26. Talbot, D. C., Smith, I. E., Nicolson, M. C., Powles, T. J., Burton, D. and Walling, J., Phase II trial of the novel sulfonylurea sulofenur in advanced breast cancer. Cancer Chemother. Pharmacol., 31, 419-422 (1993).
27. Taylor, C. W., Albert, D. S., Peng, Y. M., McCloskey, T. M., Matzner, M., Roe, D. J., Plezia, P. M., Grindey, G. B., Hamilton, M. and Seitz, D., Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. J. Natl Cancer Inst., 84, 1798-1802 (1992).
28. Tietz, N. W., Fundamentals of clinical chemistry pp 414. W. B. Saunders Co., Philadelphia (1976).